The story of Viagra and its originator, copyright, presents a complex picture for cautious investors. While the iconic drug initially generated enormous profits , its patent has lapsed , leading to generic options flooding the arena. This erosion in pricing presents a real obstacle for copyright and any fund considering a heavy holding in the compa